Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

JAMA Netw Open. 2021 Jun 1;4(6):e2113739. doi: 10.1001/jamanetworkopen.2021.13739.

Authors

Jean-Luc Raoul¹, Catherine Guérin-Charbonnel², Julien Edeline³, Victor Simmet⁴, Marine Gilabert⁵, Jean-Sébastien Frenel¹

Affiliations

¹ Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
² Oncology Data Factory & Analytics, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
³ Department of Medical Oncology, Institut Centre E. Maquis, Rennes, France.
⁴ Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.
⁵ Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.

Abstract

This cross-sectional study evaluates the prevalence of proton pump inhibitor use among patients with cancer at 4 French comprehensive cancer centers.

MeSH terms

Cross-Sectional Studies
Drug Prescriptions / statistics & numerical data*
France
Humans
Neoplasms / drug therapy*
Patient Acceptance of Health Care / statistics & numerical data
Prevalence
Proton Pump Inhibitors / administration & dosage*
Proton Pump Inhibitors / therapeutic use

Substances

Proton Pump Inhibitors